Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer: A qualitative studyShow others and affiliations
2022 (English)In: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 31, no 4, article id e13592Article in journal (Refereed) Published
Abstract [en]
OBJECTIVE: Signs and symptoms are important in monitoring prostate cancer, but there is a lack of understanding about the men's interpretation of signs and symptoms in relation to disease progression in advanced phases of the disease. The aim was to illuminate the experience of signs and symptoms in relation to disease progression in men with metastatic castration-resistant prostate cancer (mCRPC).
METHOD: Thirty longitudinal interviews were conducted with 11 men undergoing life-prolonging treatment for mCRPC. Conventional content analysis was used.
RESULTS: The results illuminate an uncertainty that the men experience when interpreting signs and symptoms. The overarching theme was The experience of an uncertain illness situation within the framework of progression, with four subthemes: Symptoms triggering thoughts about disease progression; Making sense of signs, also in the absence of symptoms; Making sense of symptoms during treatment; Progression triggering thoughts about the remainder of life.
CONCLUSION: In the uncertain illness situation, the men strive to make sense of signs and symptoms based on previous experiences and in relation to disease progression. Understanding the men's perspectives on signs and symptoms in this late phase may help health care professionals communicate about disease progression considering the balance between treatment outcome and quality of life.
Place, publisher, year, edition, pages
Wiley-Blackwell, 2022. Vol. 31, no 4, article id e13592
Keywords [en]
Metastatic castration-resistant prostate cancer, Prostate-specific antigen, Prostatic neoplasm, Qualitative research, Signs and symptoms, Uncertainty
National Category
Cancer and Oncology Nursing
Identifiers
URN: urn:nbn:se:esh:diva-9483DOI: 10.1111/ecc.13592ISI: 000780889400001PubMedID: 35411645OAI: oai:DiVA.org:esh-9483DiVA, id: diva2:1652516
Funder
The Kamprad Family Foundation, 20170260Sjöberg Foundation, 2020-01-07-05Prostatacancerförbundet
Note
Övriga forskningsfinansiärer: Villy Sundberg Foundation; Sophiahemmet ideell förening.
2022-04-192022-04-192024-06-18Bibliographically approved